Free Cash Flow: A measure of financial performance calculated as operating cash flow minus capital expenditures. Calculated as: Cash Flow from Operations + Net Property, Plant & Equipment Exp (a negative number)
BridgeBio Oncology Therapeutics, Inc (BBOT) had Free Cash Flow of $-114.50M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-134.04M |
|
-- |
|
-- |
|
$145.82M |
|
$-145.82M |
|
$11.78M |
|
$-134.04M |
|
$-134.04M |
|
$-134.04M |
|
$-134.04M |
|
$-134.04M |
|
$-134.04M |
|
$-145.82M |
|
$-145.21M |
|
31.14M |
|
31.14M |
|
$-4.30 |
|
$-4.30 |
|
| Balance Sheet Financials | |
$432.40M |
|
$0.96M |
|
$15.98M |
|
$448.38M |
|
$35.04M |
|
-- |
|
$2.24M |
|
$37.28M |
|
$411.10M |
|
$411.10M |
|
$411.10M |
|
79.99M |
|
| Cash Flow Statement Financials | |
$-113.89M |
|
$73.33M |
|
$383.40M |
|
$30.98M |
|
$373.82M |
|
$342.84M |
|
$5.87M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.34 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Free Cash Flow |
$-114.50M |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-32.61% |
|
-32.61% |
|
-29.90% |
|
-32.61% |
|
$5.14 |
|
$-3.68 |
|
$-3.66 |
|